PharmStar Pharmaceuticals, Inc. Files Patents for Advanced Aquaprin Compositions and Manufacturing Methodology

WILSON, NC--(Marketwire - June 15, 2011) -

PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced the completion of the research and development that has culminated in the filing of U.S. patents for Aquaprin formulations, compositions, and processing methodology.

PharmStar’s Chief Executive Officer, Mr. Howard Phykitt, also stated that the Company has additional product line extensions in the final development stages.

“A soluble aspirin and acetaminophen, (the active ingredient in Tylenol®) combination has been formulated to equal the active ingredients in Excedrin® but with up to 10 times faster acting results and little to no gastric intolerance,” stated Mr. Phykitt. “Both aspirin and acetaminophen are insoluble in water, but with PharmStar’s technology, both ingredients are solubilized into a clear good tasting drink in less than 30 seconds.”

About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar’s headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.

Forward-Looking Statements Disclosure
This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “will,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.


Contact:
PharmStar, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com
Investor Contact:
investors@pharmstarinc.com

MORE ON THIS TOPIC